For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Cognitively Impaired | Cognitively impaired subjects receiving a flortaucipir PET scan | 0 | None | 0 | 69 | 6 | 69 | View |
| Cognitively Normal | Cognitively normal subjects receiving a flortaucipir PET scan | 0 | None | 0 | 110 | 16 | 110 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| nasopharyngitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDRA (17.1) | View |
| procedural headache | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | MedDRA (17.1) | View |
| insomnia | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | MedDRA (17.1) | View |
| loss of bladder sensation | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | MedDRA (17.1) | View |
| hyperhidrosis | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDRA (17.1) | View |
| headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA (17.1) | View |
| dysgeusia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA (17.1) | View |
| dizziness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA (17.1) | View |
| paraesthesia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA (17.1) | View |
| injection site pain | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (17.1) | View |
| asthenia | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (17.1) | View |
| feeling abnormal | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (17.1) | View |
| gait abnormal | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (17.1) | View |
| injection site coldness | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (17.1) | View |
| blood pressure increased | SYSTEMATIC_ASSESSMENT | Investigations | MedDRA (17.1) | View |
| dry mouth | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA (17.1) | View |
| nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA (17.1) | View |
| palpitations | SYSTEMATIC_ASSESSMENT | Cardiac disorders | MedDRA (17.1) | View |